Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
Detailed price information for Sonnet Biot Inc (SONN-Q) from The Globe and Mail including charting and trades.
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its ...
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2024 Financial and Operational Review Protalix Biotherapeutics, Inc.
obj16h
Finding its rhythm: Startup seeks $4M in funding for trailblazing atrial fibrillation treatment
A new Ottawa biotech startup is seeking to raise $4 million to produce groundbreaking treatments aimed at curing one of the ...
FDA grants orphan drug designation to potential treatment of STXBP1 developmental and epileptic encephalopathy
Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...
Taiwan News19h
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Functional cure is defined by AASLD as sustained HBsAg loss and hepatitis B virus DNA <LLOQ for 6 months off-treatment. Data cut off was September 30, 2024, for lab data and October 8, 2024, for ...
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix ...
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.